Stifel Nicolaus Cuts Corcept Therapeutics (CORT) To “Hold”; Profile of 3 Analysts Covering Energy Focus, Inc. (EFOI)

Energy Focus, Inc. (NASDAQ:EFOI) Logo

Stifel Nicolaus lowered Corcept Therapeutics Inc (NASDAQ:CORT)‘s stock to a “Hold” rating. The ratings change was revealed in a a report today.

Among 9 analysts covering Energy Focus (NASDAQ:EFOI), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Energy Focus had 24 analyst reports since August 7, 2015 according to SRatingsIntel. TH Capital downgraded Energy Focus, Inc. (NASDAQ:EFOI) rating on Thursday, November 5. TH Capital has “Neutral” rating and $20.0 target. The firm earned “Buy” rating on Monday, August 15 by Rodman & Renshaw. FBR Capital initiated it with “Outperform” rating and $21.5 target in Friday, December 18 report. The stock of Energy Focus, Inc. (NASDAQ:EFOI) has “Buy” rating given on Friday, January 15 by Benchmark. The stock has “Hold” rating by Benchmark on Friday, August 12. Roth Capital downgraded Energy Focus, Inc. (NASDAQ:EFOI) on Thursday, November 5 to “Neutral” rating. As per Thursday, November 9, the company rating was maintained by Roth Capital. The firm earned “Hold” rating on Thursday, October 5 by Roth Capital. The stock has “Buy” rating by H.C. Wainwright on Friday, August 28. Oppenheimer downgraded the shares of EFOI in report on Friday, August 12 to “Hold” rating. See Energy Focus, Inc. (NASDAQ:EFOI) latest ratings:

More notable recent Energy Focus, Inc. (NASDAQ:EFOI) news were published by: Globenewswire.com which released: “Energy Focus Appoints Jerry Turin as New Chief Financial Officer” on May 22, 2018, also Streetinsider.com with their article: “Energy Focus (EFOI) Names Jerry Turin CFO” published on May 22, 2018, Globenewswire.com published: “Energy Focus, Inc. Reports First Quarter 2018 Results” on May 02, 2018. More interesting news about Energy Focus, Inc. (NASDAQ:EFOI) were released by: Crainscleveland.com and their article: “Energy Focus names Jerry Turin as chief financial officer” published on May 23, 2018 as well as Nasdaq.com‘s news article titled: “Energy Focus Releases New Line of LED Lighting Fixtures at LIGHTFAIR International 2018” with publication date: May 09, 2018.

Energy Focus, Inc., together with its subsidiaries, designs, develops, makes, markets, and sells energy-efficient lighting systems in the United States and internationally. The company has market cap of $28.53 million. It offers various light-emitting diode lighting technologies, including military maritime products, such as Military Intellitube, globe lights, berth lights, and fixtures to serve the United States navy and allied foreign navies. It currently has negative earnings. The firm also provides commercial products comprising direct-wire tubular LED (TLED) replacements for linear fluorescent lamps; Commercial Intellitube TLED replacement for linear fluorescent lamps; LED fixtures and panels for fluorescent replacement or high-intensity discharge replacement in low-bay and high-bay applications; LED down-lights; LED dock lights and wall-packs; LED vapor tight lighting fixtures; and LED retrofit kits.

Investors sentiment decreased to 1 in Q1 2018. Its down 0.67, from 1.67 in 2017Q4. It is negative, as 3 investors sold Energy Focus, Inc. shares while 6 reduced holdings. 2 funds opened positions while 7 raised stakes. 1.87 million shares or 0.66% less from 1.88 million shares in 2017Q4 were reported. Moreover, Citadel Advisors Limited Company has 0% invested in Energy Focus, Inc. (NASDAQ:EFOI) for 25,043 shares. Jacobs Levy Equity Management Inc accumulated 38,367 shares. Susquehanna Gru Ltd Liability Partnership has 40,447 shares. Savings Bank Of Ny Mellon owns 15,363 shares or 0% of their US portfolio. 3,600 are held by One Trading Lp. Peak6 Investments Lp has invested 0% in Energy Focus, Inc. (NASDAQ:EFOI). Atlantic Grp Inc Ltd Liability Corp owns 850 shares for 0% of their portfolio. Northern Trust reported 0% in Energy Focus, Inc. (NASDAQ:EFOI). Geode Cap Mngmt Ltd Liability accumulated 0% or 43,479 shares. Cambridge Advsr holds 85,253 shares. Morgan Stanley accumulated 23,676 shares. Wealthtrust Axiom Lc has 494,850 shares for 0.46% of their portfolio. Barclays Pcl has 0% invested in Energy Focus, Inc. (NASDAQ:EFOI) for 33 shares. State Treasurer State Of Michigan reported 0.01% stake. Vanguard Grp Inc accumulated 0% or 290,377 shares.

The stock increased 7.66% or $0.17 during the last trading session, reaching $2.39. About 28,501 shares traded or 126.92% up from the average. Energy Focus, Inc. (NASDAQ:EFOI) has declined 34.73% since May 31, 2017 and is downtrending. It has underperformed by 47.30% the S&P500.

Among 7 analysts covering Corcept Therapeutics (NASDAQ:CORT), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics has $3200 highest and $14 lowest target. $25’s average target is 26.97% above currents $19.69 stock price. Corcept Therapeutics had 11 analyst reports since February 2, 2017 according to SRatingsIntel. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Wednesday, October 11. Piper Jaffray has “Buy” rating and $24.0 target. On Thursday, February 2 the stock rating was initiated by Ladenburg Thalmann with “Buy”. The company was maintained on Friday, November 3 by Stifel Nicolaus. FBR Capital initiated it with “Buy” rating and $30.0 target in Thursday, March 8 report. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) on Thursday, August 24 with “Buy” rating. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Friday, September 8. Piper Jaffray has “Buy” rating and $24.0 target. The stock has “Buy” rating by FBR Capital on Tuesday, March 20. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) earned “Buy” rating by Seaport Global on Friday, April 13.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on August, 7. They expect $0.16 EPS, up 60.00% or $0.06 from last year’s $0.1 per share. CORT’s profit will be $18.44M for 30.77 P/E if the $0.16 EPS becomes a reality. After $0.14 actual EPS reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 14.29% EPS growth.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Streetinsider.com which released: “Stifel Downgrades Corcept Therapeutics (CORT) to Hold” on May 31, 2018, also Seekingalpha.com with their article: “Reader Inquiry: What’s In Store For Corcept Therapeutics?” published on May 21, 2018, Seekingalpha.com published: “Corcept Therapeutics’ (CORT) CEO Joseph Belanoff on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Nasdaq.com and their article: “Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial …” published on May 17, 2018 as well as Bizjournals.com‘s news article titled: “Gilead, BioMarin among Bay Area drug makers shamed by FDA in generics ‘gaming’ list” with publication date: May 17, 2018.

The stock increased 5.35% or $1 during the last trading session, reaching $19.69. About 1.02M shares traded. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since May 31, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Investors sentiment decreased to 1.28 in Q1 2018. Its down 0.21, from 1.49 in 2017Q4. It turned negative, as 28 investors sold Corcept Therapeutics Incorporated shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported. Michigan-based Comerica Bancorp has invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Mckinley Capital Mngmt Ltd Liability Delaware invested in 0.01% or 6,774 shares. New York-based American Grp Incorporated has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Jpmorgan Chase And has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Us Bancorporation De accumulated 4,648 shares. Sit Inv Associates Incorporated has 95,650 shares for 0.04% of their portfolio. Advisory Svcs Networks Limited Liability Com owns 47 shares or 0% of their US portfolio. State Board Of Administration Of Florida Retirement has 0% invested in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 51,163 shares. Farmers & Merchants owns 380 shares. Prudential Fincl reported 429,873 shares stake. 46,655 are owned by Citigroup. Amp Capital Investors accumulated 20,047 shares. Virginia Retirement Systems Et Al has 84,200 shares. Millennium Management Limited Liability Company holds 0.01% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 601,408 shares. California-based Clarivest Asset Management Limited Liability Corporation has invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $2.27 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 18.93 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: